Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report

Published: November 30, 2022 Report Code: GDGMDHC22401IDB-ST

Select Item

Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. The Hypertension pipeline market research report provides comprehensive information on the therapeutics under development for Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypertension and features dormant and discontinued projects.

Hypertension Pipeline Products Market Segmentation by Targets

The key targets in the Hypertension pipeline products market are Type 1 Angiotensin II Receptor, Voltage Dependent L Type Calcium Channel, Prostacyclin Receptor, 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase, cGMP Specific 3′,5′ Cyclic Phosphodiesterase, Solute Carrier Family 12 Member 3, Soluble Guanylate Cyclase, Endothelin 1 Receptor, Platelet Derived Growth Factor Receptor, and Beta 1 Adrenergic Receptor, among others. Type 1 Angiotensin II Receptor has the highest number of products in the Hypertension pipeline products market.

Hypertension Pipeline Products Market Analysis by Targets

Hypertension Pipeline Products Market Analysis by Targets

For more target insights into the Hypertension pipeline products market, download a free report sample

Hypertension Pipeline Products Market Segmentation by Mechanisms of Action

The key mechanisms of action in the Hypertension pipeline products market are Type 1 Angiotensin II Receptor Antagonist, Voltage Dependent L Type Calcium Channel Blocker, Prostacyclin Receptor Agonist, 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase Inhibitor, cGMP Specific 3′,5′ Cyclic Phosphodiesterase Inhibitor, Solute Carrier Family 12 Member 3 Inhibitor, Soluble Guanylate Cyclase Activator, Endothelin 1 Receptor Antagonist, Beta 1 Adrenergic Receptor Antagonist, and Cytochrome P450 11B2 Mitochondrial Inhibitor, among others. Type 1 Angiotensin II Receptor Antagonist leads the Hypertension pipeline products market in terms of MoA.

Hypertension Pipeline Products Market Analysis by Mechanisms of Action

Hypertension Pipeline Products Market Analysis by Mechanisms of Action

For more mechanisms of action insights into the Hypertension pipeline products market, download a free report sample

Hypertension Pipeline Products Market Segmentation by Routes of Administration

The key routes of administration in the Hypertension pipeline products market are oral, intravenous, inhalational, subcutaneous, intramuscular, parenteral, topical, nasal, intracoronary, and intradermal, among others. Oral leads the Hypertension pipeline products market in terms of RoA.

Hypertension Pipeline Products Market Analysis by Routes of Administration

Hypertension Pipeline Products Market Analysis by Routes of AdministrationFor more routes of administration insights into the Hypertension pipeline products market, download a free report sample

Hypertension Pipeline Products Market Segmentation by Molecule Types

The key molecule types in the Hypertension pipeline products market are small molecule, fusion protein, monoclonal antibody, synthetic peptide, antisense RNAi oligonucleotide, peptide, recombinant protein, oligonucleotide, biologic, and gene therapy, among others. Small molecule leads the Hypertension pipeline products market in terms of molecule type.

Hypertension Pipeline Products Market Analysis by Molecule Types

Hypertension Pipeline Products Market Analysis by Molecule TypesFor more molecule type insights into the Hypertension pipeline products market, download a free report sample

Hypertension Pipeline Products Market - Competitive Landscape

Some of the leading companies in the Hypertension pipeline products market are Addpharma Inc, United Therapeutics Corp, Bayer AG, Hanmi Pharmaceuticals Co Ltd, Merck & Co Inc, Boryung Pharmaceutical Co Ltd, Celltrion Inc, Chong Kun Dang Pharmaceutical Corporation, Daiichi Sankyo Co Ltd, and Johnson & Johnson. Addpharma Inc is the leading company in the Hypertension pipeline products market.

Hypertension Pipeline Products Market Analysis by Companies

Hypertension Pipeline Products Market Analysis by Companies

To know more about the leading players in the Hypertension pipeline products market, download a free report sample

Hypertension Pipeline Products Market Report Overview

Key Targets Type 1 Angiotensin II Receptor, Voltage Dependent L Type Calcium Channel, Prostacyclin Receptor, 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase, cGMP Specific 3′,5′ Cyclic Phosphodiesterase, Solute Carrier Family 12 Member 3, Soluble Guanylate Cyclase, Endothelin 1 Receptor, Platelet Derived Growth Factor Receptor, and Beta 1 Adrenergic Receptor
Key Mechanisms of Action Type 1 Angiotensin II Receptor Antagonist, Voltage Dependent L Type Calcium Channel Blocker, Prostacyclin Receptor Agonist, 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase Inhibitor, cGMP Specific 3′,5′ Cyclic Phosphodiesterase Inhibitor, Solute Carrier Family 12 Member 3 Inhibitor, Soluble Guanylate Cyclase Activator, Endothelin 1 Receptor Antagonist, Beta 1 Adrenergic Receptor Antagonist, and Cytochrome P450 11B2 Mitochondrial Inhibitor
Key Routes of Administration Oral, Intravenous, Inhalational, Subcutaneous, Intramuscular, Parenteral, Topical, Nasal, Intracoronary, and Intradermal
Key Molecule Type Small Molecule, Fusion Protein, Monoclonal Antibody, Synthetic Peptide, Antisense RNAi Oligonucleotide, Peptide, Recombinant Protein, Oligonucleotide, Biologic, and Gene Therapy
Leading Companies Addpharma Inc, United Therapeutics Corp, Bayer AG, Hanmi Pharmaceuticals Co Ltd, Merck & Co Inc, Boryung Pharmaceutical Co Ltd, Celltrion Inc, Chong Kun Dang Pharmaceutical Corporation, Daiichi Sankyo Co Ltd, and Johnson & Johnson

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertension (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Hypertension (Cardiovascular)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Hypertension (Cardiovascular).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding the Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

35Pharma Inc
Aadi Bioscience Inc
Abivax SA
Addpharma Inc
Adepthera LLC
Adhera Therapeutics Inc
Advent Therapeutics Inc
Aeon Respire Inc
Aerami Therapeutics Inc
Aerogen Pharma Corp
Aerovate Therapeutics Inc
Aggamin LLC
Ahn-Gook Pharmaceutical Co Ltd
AI Therapeutics Inc
Ajanta Pharma Ltd
Aju Pharm Co Ltd
Alchemedicine Co Ltd
Algorithm Sciences Inc
Alnylam Pharmaceuticals Inc
Altavant Sciences Inc
Alterras Therapeutics GmbH
Alveolus Bio Inc
Amgen Inc
Anagenics Ltd
AnGes Inc
Angion Biomedica Corp
Antlia Bioscience Inc
AOBiome LLC
Apaxen
APEIRON Biologics AG
Apollo Therapeutics LLC
APT Therapeutics Inc
Aqualung Therapeutics Corp
Argo Biopharma Australia Pty Ltd
Arovella Therapeutics Ltd
AstraZeneca Plc
Attgeno AB
ATXA Therapeutics Ltd
Autotelic Bio Inc
Avirmax Inc
Bayer AG
Bial - Portela & Ca SA
Biogen Inc
BioRestorative Therapies Inc
Biozeus Pharmaceutical SA
Boehringer Ingelheim International GmbH
Boryung Pharmaceutical Co Ltd
Brainfarma Chemical and Pharmaceutical Industry SA
C4X Discovery Holdings Plc
Camurus AB
Capricor Therapeutics Inc
CardioPharma Inc
Cardiorentis AG
CellionBioMed Inc
Celltrion Inc
Celon Pharma SA
Celtaxsys Inc
Centessa Pharmaceuticals Plc
Cereno Scientific AB
Chengdu Dikang Pharmaceuticals Co Ltd
Chiesi Farmaceutici SpA
Chong Kun Dang Pharmaceutical Corporation
CinCor Pharma Inc
Claritas Pharmaceuticals Inc
Closed Loop Medicine Ltd
Cloud Pharmaceuticals Inc
Comanche Biopharma Corp
Corsair Pharma Inc
Cumberland Pharmaceuticals Inc
D. Western Therapeutics Institute Inc
Daewon Pharmaceutical Co Ltd
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Denovo Biopharma LLC
Dilafor AB
Dong-A ST Co Ltd
DongKoo Bio & Pharma Co Ltd
Dongkook Pharmaceutical Co Ltd
Eldrug SA
Eli Lilly and Co
Excubio Pharmaceuticals Inc
Fauna Bio
Ferring Pharmaceuticals Inc
FunPep Co Ltd
Galectin Therapeutics Inc
GenKyoTex SA
GenThera Inc
Genuone Science Co Ltd
George Medicines Pty Ltd
GEXVal Inc
Gilead Sciences Inc
Gmax Biopharm LLC
Gossamer Bio Inc
Guangdong East Sunshine Pharmaceutical Co Ltd
Guangzhou Magpie Pharmaceutical Co Ltd
Guangzhou Yipinhong Pharmaceutical Co Ltd
H. Lundbeck AS
Hanlim Pharm Co Ltd
Hanmi Pharmaceuticals Co Ltd
Hetero Drugs Ltd
Himuka AM Pharma Corp
HK inno.N Corp
Huons Co Ltd
Hyalos Therapeutics Inc
Idorsia Pharmaceutical Ltd
Ildong Pharmaceutical Co Ltd
Imagine Pharma LLC
Imunon Inc
Innolife Co Ltd
Innopharmax Inc
Innovative Pharmacology Research
Insmed Inc
Interprotein Corp
INVENT Pharmaceuticals Inc
Ionis Pharmaceuticals Inc
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
JW Pharmaceutical Corp
KARE Biosciences Inc
KBP Biosciences Co Ltd
Keros Therapeutics Inc
Kolmar Korea Co Ltd
Kuhnil Pharmaceutical Co Ltd
Kyowa Kirin Co Ltd
Kyung Dong Co Ltd
Laboratorios Silanes SA de CV
Larix Bioscience LLC
Lempo Therapeutics Ltd
Les Laboratoires Servier SAS
Lexaria Bioscience Corp
Liaoning Haiwang Biotechnoloty Co Ltd
Liquidia Technologies Inc
LTT Bio-Pharma Co Ltd
Luckwel Pharmaceuticals Inc
Lyndra Therapeutics Inc.
Merck & Co Inc
Mineralys Therapeutics Inc
Morphic Therapeutic Inc
NA Vaccine Research Institute Co Ltd
Nadian Bio Ltd
Nanjing Yoko Biomedical Co Ltd
NeuroBo Pharmaceuticals Inc
Nippon Shinyaku Co Ltd
Nissan Chemical Corp
Northern Therapeutics Inc
Novartis AG
NuSirt Biopharma Inc
NVP Healthcare Co Ltd
Omeros Corp
Orion Corp
Overseas Pharmaceuticals Ltd
Panorama Researchama Research
PharmaIN Corp
Pharming Group NV
Pharmosa Biopharm Inc
PhaseBio Pharmaceuticals Inc
PRM Pharma LLC
Proteo Biotech AG
PulmoSIM Therapeutics
Q BioMed Inc
Qanatpharma GmbH
Quantum Genomics SA
Radikal Therapeutics Inc
Reata Pharmaceuticals Inc
Recursion Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Renova Therapeutics Inc
Respira Therapeutics Inc
Resverlogix Corp
Reviva Pharmaceuticals Inc
Ribomic Inc
RMJ Holdings LLC
Samik Pharmaceutical Co Ltd
Sanofi
Sardocor Corp
Sarfez Pharmaceuticals Inc
Scohia Pharma Inc
Shaanxi Micot Technology Co Ltd
Shanghai Pharmaceutical Group Co Ltd
Shanghai Pharmaceuticals Holding Co Ltd
Shanghai Xinyi Pharmaceutical Co Ltd
Shenzhen Evergreen Therapeutics Co Ltd
Shenzhen Salubris Pharmaceuticals Co Ltd
Shiftbio Co Ltd
Shijiazhuang Sagacity New Drug Development Co Ltd
Shin Poong Pharm Co Ltd
Sirnaomics Ltd
SJT Molecular Research SL
Sorrento Therapeutics Inc
SteadyMed Therapeutics Inc
Structure Therapeutics Inc
Sulfateq BV
Synokem Pharmaceuticals Ltd
Systimmune Inc
Takeda Pharmaceutical Co Ltd
Target Medicals
Tenax Therapeutics Inc
Theracos Inc
Theravance Biopharma Inc
Topadur Pharma AG
Torrent Pharmaceuticals Ltd
Translate Bio Inc
Triastek Inc
Tris Pharma Inc
Tritech Biopharmaceuticals Co Ltd
United Therapeutics Corp
Vascular BioSciences
Vasculonics LLC
VasThera Co Ltd
Vectus Biosystems Ltd
Vicore Pharma AB
Vifor Pharma Ltd
Vivus LLC
Voronoi Group
Windtree Therapeutics Inc
Worphmed Srl
Wuhan Langlai Technology Development Co Ltd
XuanZhu Biological Technology Co Ltd
Yungjin Pharm Co Ltd
Zumbro Discovery Inc
Zuventus Healthcare Ltd
Zymedi

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hypertension – Overview

Hypertension – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hypertension – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hypertension – Companies Involved in Therapeutics Development

Hypertension – Drug Profiles

Hypertension – Dormant Projects

Hypertension – Discontinued Products

Hypertension – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Hypertension, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Hypertension – Dormant Projects, 2022

Hypertension – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Hypertension, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

  • What are the key targets in the Hypertension pipeline products market?

    The key targets in the Hypertension pipeline products market are Type 1 Angiotensin II Receptor, Voltage Dependent L Type Calcium Channel, Prostacyclin Receptor, 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase, cGMP Specific 3′,5′ Cyclic Phosphodiesterase, Solute Carrier Family 12 Member 3, Soluble Guanylate Cyclase, Endothelin 1 Receptor, Platelet Derived Growth Factor Receptor, and Beta 1 Adrenergic Receptor, among others.

  • What are the key mechanisms of action in the Hypertension pipeline products market?

    The key mechanisms of action in the Hypertension pipeline products market are Type 1 Angiotensin II Receptor Antagonist, Voltage Dependent L Type Calcium Channel Blocker, Prostacyclin Receptor Agonist, 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase Inhibitor, cGMP Specific 3′,5′ Cyclic Phosphodiesterase Inhibitor, Solute Carrier Family 12 Member 3 Inhibitor, Soluble Guanylate Cyclase Activator, Endothelin 1 Receptor Antagonist, Beta 1 Adrenergic Receptor Antagonist, and Cytochrome P450 11B2 Mitochondrial Inhibitor, among others.

  • What are the key routes of administration in the Hypertension pipeline products market?

    The key routes of administration in the Hypertension pipeline products market are oral, intravenous, inhalational, subcutaneous, intramuscular, parenteral, topical, nasal, intracoronary, and intradermal, among others.

  • What are the key molecule types in the Hypertension pipeline products market?

    The key molecule types in the Hypertension pipeline products market are small molecule, fusion protein, monoclonal antibody, synthetic peptide, antisense RNAi oligonucleotide, peptide, recombinant protein, oligonucleotide, biologic, and gene therapy, among others.

  • Which are the leading companies in the Hypertension pipeline products market?

    Some of the leading companies in the Hypertension pipeline products market are Addpharma Inc, United Therapeutics Corp, Bayer AG, Hanmi Pharmaceuticals Co Ltd, Merck & Co Inc, Boryung Pharmaceutical Co Ltd, Celltrion Inc, Chong Kun Dang Pharmaceutical Corporation, Daiichi Sankyo Co Ltd, and Johnson & Johnson.

Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Cardiovascular reports
Pharmaceuticals
New
New Drug Approvals and Their Contract Manufacture - 2024 Edition
$4,995 | April 2024
Pharmaceuticals
New
Methicillin-Resistant Staphylococcus aureus (MRSA) Epidemiology Analysis and Forecast to 2033
$3,995 | April 2024
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more